PsychiatryAddiction
Opioid Use Disorder
Opioid substitution therapy (methadone / buprenorphine), naloxone provision, harm reduction, comorbidity.
Source: Orange Book (Drug misuse and dependence — UK guidelines on clinical management 2017); NICE NG241
Step 1 of ~4
info
Assessment
DSM-5 OUD: ≥2 criteria within 12 months: tolerance, withdrawal, larger use than intended, persistent desire to cut down, time spent obtaining, social/occupational impact, continued use despite harm, hazardous use, craving, role failure, interpersonal problems, withdrawal of activities. Severity by criteria count: mild 2–3, moderate 4–5, severe ≥6.
Baseline:
• Bloods: FBC, U&E, LFTs, BBV (HIV, HBV, HCV), syphilis.
• Urine drug screen.
• Pregnancy test in women.
• ECG (QTc — methadone risk).
• Mental health screening.
• Social: housing, family, employment, criminal justice.
• Domestic abuse + safeguarding (children at home).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Buprenorphine (Opioid Dependence) · Partial Opioid Agonist (Opioid Substitution Therapy)
- Buprenorphine / Naloxone (Sublingual) · Opioid Partial Agonist — Opioid Substitution Therapy (OST)
- Buprenorphine · Opioid partial agonist (μ-receptor partial agonist, κ-antagonist)
- Buprenorphine with naloxone · Partial mu-agonist + opioid antagonist (opioid dependence)
- Naloxone (Intravenous — Opioid Reversal) · Opioid Receptor Antagonist
- Naloxone · Opioid Antagonist
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF
Decision support only. Always apply local guidelines and clinical judgement.